SG/CALL/BRISTOL-MYERS SQUIBB/50/0.1/21.03.25 | Market Closed - Deutsche Boerse AG 03:36:08 2024-06-28 pm EDT | ||
| 0.13 EUR | 0.00% |
|
| Current month | +8.33% | ||
| 3 months | -79.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.13 | 0.00% |
| 24-06-27 | 0.13 | -13.33% |
| 24-06-26 | 0.15 | +7.14% |
| 24-06-25 | 0.14 | 0.00% |
| 24-06-24 | 0.14 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:36 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3VWA |
| ISIN | DE000SW3VWA5 |
| Date issued | 2023-09-22 |
| Strike | 50 $ |
| Maturity | 2025-03-21 (266 Days) |
| Parity | 10 : 1 |
| Emission price | 1.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.24 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.01 € |
| Spread % | 7.69% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.51
USD
Average target price
53.19
USD
Spread / Average Target
+28.15%
- Stock Market
- Warrants
- Warrant
